**Supplementary Table 2:** Quality of life decrements included in the model

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameter | Base casevalue | ProbabilisticDistribution | One-way sensitivity Range | Source |
|  |  |  |  |  |
| Local spread prostate cancer | 0.16 | Beta | 0.13-0.19 | ([17](#_ENREF_17)) |
| Metastatic spread prostate cancer | 0.33 | Beta | 0.26-0.40 | ([17](#_ENREF_17)) |
| Radiation treatment for prostate cancer | 0.27 | Beta | 0.22-0.32 | ([17](#_ENREF_17))  |
| Hormone treatment for prostate cancer | 0.17 | Beta | 0.14-0.20 | ([17](#_ENREF_17))  |
| Bowel problems from treatment (proportion who experience it after radiation treatment)(proportion who experience it after hormone treatment) | 0.29 (0.08)(0.00) | Beta(beta)(n/a) | 0.23-0.35(0.04-0.29)(n/a) | (26-29) Expert Opinion([17](#_ENREF_17))  |
| Impotence from treatment (proportion who experience it after radiation treatment)(proportion who experience it after hormone treatment) | 0.11(0.67)(1.00) | Beta(beta)(n/a) | 0.09-0.13(0.64-0.90)(n/a) | (26-29) Expert Opinion([17](#_ENREF_17)) |
| Incontinence from treatment (proportion who experience it after radiation treatment)(proportion who experience it after hormone treatment) | 0.17(0.13)(0.00) | Beta(beta)(n/a) | 0.14-0.20(0.04-0.33)(n/a) | (26-29) Expert Opinion([17](#_ENREF_17)) |
| Terminal prostate cancer | 0.75 | Beta | 0.60-0.90 | ([17](#_ENREF_17)) |
| Terminal – all cause mortality (ages 65-84) | 0.54 | Beta | 0.42-0.65 | ([35-39](#_ENREF_35)) |
| Terminal – all cause mortality (ages 85+) | 0.65 | Beta | 0.57-0.70 | ([35-39](#_ENREF_35)) |
| Death  | 1 | n/a | n/a | Expert Opinion |